ELAVL4

Protein identityUniProt · HPA

UniProt accession

P26378

Gene

ELAVL4

Ensembl

ENSG00000162374

Chromosome

1

Canonical length

385 aa

Protein class

Predicted intracellular proteins

Subcellular location

Nucleoplasm,Vesicles

OverviewNCBI Gene

Enables mRNA 3'-UTR AU-rich region binding activity; poly(A) binding activity; and pre-mRNA intronic pyrimidine-rich binding activity. Involved in 3'-UTR-mediated mRNA stabilization; RNA processing; and positive regulation of 3'-UTR-mediated mRNA stabilization. Predicted to be located in axon; cytoplasm; and dendrite. Predicted to be part of ribonucleoprotein complex. Predicted to be active in glutamatergic synapse. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

385 residues, UniProt reviewed canonical sequence.

>P26378|ELAVL4
     1  MEWNGLKMII STMEPQVSNG PTSNTSNGPS SNNRNCPSPM QTGATTDDSK TNLIVNYLPQ
    61  NMTQEEFRSL FGSIGEIESC KLVRDKITGQ SLGYGFVNYI DPKDAEKAIN TLNGLRLQTK
   121  TIKVSYARPS SASIRDANLY VSGLPKTMTQ KELEQLFSQY GRIITSRILV DQVTGVSRGV
   181  GFIRFDKRIE AEEAIKGLNG QKPSGATEPI TVKFANNPSQ KSSQALLSQL YQSPNRRYPG
   241  PLHHQAQRFR LDNLLNMAYG VKRLMSGPVP PSACPPRFSP ITIDGMTSLV GMNIPGHTGT
   301  GWCIFVYNLS PDSDESVLWQ LFGPFGAVNN VKVIRDFNTN KCKGFGFVTM TNYDEAAMAI
   361  ASLNGYRLGD RVLQVSFKTN KAHKS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ELAVL4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability

Intracellular

Secreted

No

Transmembrane segments

0

Mean surface accessibility (rSASA)

0.45

Highest tissue expression

38 nTPM

Expression across tissuesHPA

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ELAVL4.

Disease | ImmuneIEDB

Conditions an epitope on ELAVL4 was assayed in.

• lung cancer B cell
• HTLV-1-associated myelopathy/tropical spastic paraparesis T cell
• central nervous system cancer T cell
• lung oat cell carcinoma T cell

Disease | AutoantibodyPubMed

Conditions in which antibodies against ELAVL4 are reported. Each links to that disease's full target list.

• Lung Neoplasms 79
• Paraneoplastic Syndromes, Nervous System 35
• Limbic Encephalitis 15
• Peripheral Nervous System Diseases 12
• Encephalitis 9
• Autoimmune Diseases of the Nervous System 6
• Adenocarcinoma 4
• Brain Diseases 4
• Breast Neoplasms 4
• Multiple Sclerosis 4
• Neoplasm Recurrence, Local 4
• Epilepsy 3
• Polyneuropathies 3
• Sjogren's Syndrome 3

Showing 14 of 30 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for ELAVL4 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)

0.38

gnomAD pLI

0.91

gnomAD missense Z

2.85

DepMap mean gene effect

-0.01

DepMap dependency class

none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

• 3'-UTR-mediated mRNA stabilization
• cerebral cortex neuron differentiation
• dendrite morphogenesis
• learning
• locomotory behavior
• mRNA processing
• positive regulation of 3'-UTR-mediated mRNA stabilization
• RNA processing
• RNA splicing

Molecular functions

• mRNA 3'-UTR AU-rich region binding
• mRNA 3'-UTR binding
• poly(A) binding
• pre-mRNA intronic pyrimidine-rich binding

Cellular components

• axon
• cytoplasm
• dendrite
• growth cone
• perikaryon
• ribonucleoprotein complex

Protein domainsUniProt · Pfam · InterPro

• RNA recognition motif domain
• Paraneoplastic encephalomyelitis antigen
• Splicing factor ELAV/Hu
• Nucleotide-binding alpha-beta plait domain superfamily
• RNA-binding domain superfamily
• RNA recognition motif
• HuD, RNA recognition motif 3

KeywordsUniProt

• Cell projection
• Cytoplasm
• Methylation
• mRNA processing
• mRNA splicing
• Phosphoprotein
• Repeat
• RNA-binding

InteractionsUniProt · HPA

Protein binding partners of ELAVL4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

• EIF4A
• SMN
• MAP1A
• IGF2BP1